Open AccessFracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis
Author(s) -
Lisa-Ann Fraser,
Kelly Vogt,
Rick Adachi,
Lehana Thabane
Publication year - 2011
Publication title -
therapeutics and clinical risk management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.719
H-Index - 55
eISSN - 1178-203X
pISSN - 1176-6336
DOI - 10.2147/tcrm.s19385
Subject(s) - medicine , discontinuation , relative risk , osteoporosis , meta analysis , adverse effect , bisphosphonate , confidence interval , randomized controlled trial , number needed to harm , physical therapy , number needed to treat
The risks and benefits of continuing bisphosphonate therapy beyond 5 years in patients with primary osteoporosis have not been well established.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom